Clinical Pharmacology: Current Topics and Case Studies (Record no. 112966)
[ view plain ]
| 000 -LEADER | |
|---|---|
| fixed length control field | 03771nam a22004335i 4500 |
| 001 - CONTROL NUMBER | |
| control field | 978-3-7091-0144-5 |
| 003 - CONTROL NUMBER IDENTIFIER | |
| control field | DE-He213 |
| 005 - DATE AND TIME OF LATEST TRANSACTION | |
| control field | 20140220084552.0 |
| 007 - PHYSICAL DESCRIPTION FIXED FIELD--GENERAL INFORMATION | |
| fixed length control field | cr nn 008mamaa |
| 008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION | |
| fixed length control field | 110203s2010 au | s |||| 0|eng d |
| 020 ## - INTERNATIONAL STANDARD BOOK NUMBER | |
| International Standard Book Number | 9783709101445 |
| -- | 978-3-7091-0144-5 |
| 024 7# - OTHER STANDARD IDENTIFIER | |
| Standard number or code | 10.1007/978-3-7091-0144-5 |
| Source of number or code | doi |
| 050 #4 - LIBRARY OF CONGRESS CALL NUMBER | |
| Classification number | RM1-950 |
| 072 #7 - SUBJECT CATEGORY CODE | |
| Subject category code | MMG |
| Source | bicssc |
| 072 #7 - SUBJECT CATEGORY CODE | |
| Subject category code | MED071000 |
| Source | bisacsh |
| 082 04 - DEWEY DECIMAL CLASSIFICATION NUMBER | |
| Classification number | 615 |
| Edition number | 23 |
| 100 1# - MAIN ENTRY--PERSONAL NAME | |
| Personal name | Müller, Markus. |
| Relator term | editor. |
| 245 10 - TITLE STATEMENT | |
| Title | Clinical Pharmacology: Current Topics and Case Studies |
| Medium | [electronic resource] / |
| Statement of responsibility, etc | edited by Markus Müller. |
| 264 #1 - | |
| -- | Vienna : |
| -- | Springer Vienna, |
| -- | 2010. |
| 300 ## - PHYSICAL DESCRIPTION | |
| Extent | XXIV, 430 p. |
| Other physical details | online resource. |
| 336 ## - | |
| -- | text |
| -- | txt |
| -- | rdacontent |
| 337 ## - | |
| -- | computer |
| -- | c |
| -- | rdamedia |
| 338 ## - | |
| -- | online resource |
| -- | cr |
| -- | rdacarrier |
| 347 ## - | |
| -- | text file |
| -- | |
| -- | rda |
| 505 0# - FORMATTED CONTENTS NOTE | |
| Formatted contents note | The discipline of Clinical Pharmacology -- Current issues in drug development -- Current issues in drug regulation -- Current issues in drug reimbursement -- Clinical Trials -- Ethics in clinical research -- Good Clinical Practice (GCP) and scientific misconduct -- Phase-I studies and first-in-human trials -- Clinical trials - interventional studies -- Observational studies -- Pharmacokinetics I: PK-PD approaches - antibiotic drug development -- Pharmacokinetics II: 14C-labelled microdosing in assessing drug pharmacokinetics at Phase-0 -- Epidemiology and bio statistics -- Placebo effects and placebo control in clinical trials -- Tools in Clinical Pharmacology -- Tools in clinical pharmacology - imaging techniques -- Current concepts of pharmacogenetics, pharmacogenomics, and the “druggable” genome -- Biomarkers -- Molecular tools in drug research — translational medicine -- Topics in Clinical Pharmacology -- Pharmaceutical drug safety -- Drug interactions medicine -- “Non-chemical” drugs: biologicals, protein therapeutics, vaccines and antisense therapeutics -- Development of Advanced Therapy Medicinal Products — a case for early scientific advice -- Individualized medicine -- Generics, biosimilars, enantiomers and me-toos -- Special situations, market fragmentation I: orphan drugs for rare diseases -- Special situations, market fragmentation II: sex differences -- Special situations III: Medicines for Children. |
| 520 ## - SUMMARY, ETC. | |
| Summary, etc | Today we witness an eventful time in which the powerful new forces of genomics, information technology and economics are rapidly changing the science and art of medicine. This will require more specialization than ever before. However, there is also an increasing demand for an integrated approach, which is provided by the discipline of Clinical Pharmacology (CP). CP pursues a scientific goal by studying drug action in patients and volunteers, a clinical goal by administering appropriate drug therapy and a regulatory goal by assessing the risk/benefit ratio of drug candidates in drug development and reimbursement. This introduction to current topics of CP covers traditional topics of clinical drug research and trial methodology but also provides insight in current topics like genomics, imaging technology and issues in drug reimbursement. A number of concrete case studies in clinical drug research and development help to give a better understanding of the general principles of CP. |
| 650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name as entry element | Medicine. |
| 650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name as entry element | Toxicology. |
| 650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name as entry element | Pharmacy. |
| 650 14 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name as entry element | Biomedicine. |
| 650 24 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name as entry element | Pharmacology/Toxicology. |
| 650 24 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name as entry element | Pharmacy. |
| 710 2# - ADDED ENTRY--CORPORATE NAME | |
| Corporate name or jurisdiction name as entry element | SpringerLink (Online service) |
| 773 0# - HOST ITEM ENTRY | |
| Title | Springer eBooks |
| 776 08 - ADDITIONAL PHYSICAL FORM ENTRY | |
| Display text | Printed edition: |
| International Standard Book Number | 9783709101438 |
| 856 40 - ELECTRONIC LOCATION AND ACCESS | |
| Uniform Resource Identifier | http://dx.doi.org/10.1007/978-3-7091-0144-5 |
| 912 ## - | |
| -- | ZDB-2-SBL |
No items available.